Navigation Links
US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness
Date:9/19/2007

n the early stage of the disease. Because pafuramidine is more user-friendly than existing therapies, we anticipate that it would be available in community clinics as well as at current African sleeping sickness treatment centers. Patients could be treated close to home, rather than traveling long distances to specialized centers."

Pafuramidine has previously been granted Orphan Drug Designation for treatment of pneumocystis pneumonia (PCP) and malaria. In addition to trials for African sleeping sickness, pafuramidine is currently in Phase III clinical trials for PCP, and in Phase II trials targeting malaria treatment and malaria prophylaxis.

"This is another positive milestone for Immtech as pafuramidine advances towards commercialization," commented Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer. "We will continue to work closely with our consortium of scientists, and global collaborators to develop safer and more effective therapies for this and other global health threats."

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African Sleeping Sickness), and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com

"Safe Harbor" Statement under the Private Securities Reform Ac
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
5. Point of Care Strep Tests Speed Treatment, Lower Costs
6. Rapid HIV Testing Increases Possibility of Treatment
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)...  The North Shore-LIJ Health System is expanding a ... at North Shore University Hospital in Manhasset, ... at Forest Hills (NY) Hospital. ... new pilot program strengthens patient safety by providing hospitals ... first time in the US that remote video auditing ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Young drivers ... higher risk of getting into car crashes, but Australian ... sleep on weekends puts them in even greater danger ... another challenge to adolescents that comes with lack of ... of the Center for Injury Research and Prevention at ...
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Long-acting ... chronic obstructive pulmonary disease (COPD) may raise the ... new large Canadian study reveals. The finding ... prescribed long-acting bronchodilators -- either anticholinergics (such as ... are commonly used to relieve the shortness of ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... (HealthDay News) -- Racial disparities exist in the treatment ... United States, according to a large new study. ... part of their initial treatment, researchers found that blacks ... surgery in the early stages of the disease. Hispanics ... and stage 2 disease than white patients. "In ...
(Date:5/21/2013)... The surgical management of non-small cell lung cancer ... race of the patient, according to a new study., ... and Stage II NSCLC is surgery," said researcher Jayanth ... Omaha, Nebraska. "In our study of more than 1,200,000 ... years 2000 and 2010, we found statistically significant racial ...
Breaking Medicine News(10 mins):Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... The first results of the first European survey of cancer ... 6th congress of the European Federation of Chapters of the ... surveys have looked at the overall management of pain in ... look in detail at Breakthrough Cancer Pain (BTCP) from a ...
... ... Proactive Wellness Centers, PLC -- a leading Anti-Aging Practice, is the featured speaker at ... in Northern Virginia. , ... Sterling, VA (PRWEB) September 11, 2009 -- Most women understand that health factors ...
... ... specialist Flintec has recruited eight new software and electronic developers to ... equipment is Flintec,s fastest growing area of business. Increasing numbers of ... build the precision measuring systems at the heart of their life-saving ...
... , , NEW YORK, Sept. ... and The Mount Sinai Medical Center describe the Community Diabetes ... outreach program which was designed specifically for people from the vulnerable ... Twenty-five patients from The Mount Sinai Medical Center were randomly ...
... , , , ... industry leader, declared his support for H.R. 1891, a House bill ... deduction. Roeser is Senior Vice President of Marketing and Operations for ... -- one of the nation,s largest and most experienced long-term care ...
... , VOORHEES, N.J., Sept. 10 Angioedema is ... organs, and airway, causing discomfort and even death as a result ... the prevention and treatment of angioedema, and new therapies are being ... patient population. , , To address the need ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:Dr. Lynese Lawson Speaks to Sterling Women: Strategies to Rejuvenate Your Health and Your Career 2Health News:Dr. Lynese Lawson Speaks to Sterling Women: Strategies to Rejuvenate Your Health and Your Career 3Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 2Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 3Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 4Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:Industry Leader Praises Health Reform Bill that Provides 50% Tax Deduction for Long-Term Care Premiums 2Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2
... The BladderScan BVM 6500 ... noninvasively to determine UEBW ... and bladder volume using ... BVM 6500 was designed ...
... Titan™ Inflatable Penile Prosthesis (IPP) ... to be surgically implanted into ... of erectile dysfunction (also known ... the patient with voluntary control ...
... Alpha I continues to be a proven, ... Alpha I to have mechanical reliability rates ... first-time implants. ioflex material contributes to excellent ... Thats because Bioflex: ,Provides maximum, controlled girth ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
Medicine Products: